Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
John, Thomas
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma	Active, not recruiting	3	214	US, RoW	Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo	PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney	Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma	06/25	02/26
NCT02824965: Pembrolizumab + CVA21 in Advanced NSCLC From KEYNOTE-200 study in combination with CVA21 for NSCLC and bladder cancer [screenshot] Nov 2017 - Nov 2017: From KEYNOTE-200 study in combination with CVA21 for NSCLC and bladder cancer [screenshot]	Active, not recruiting	1/2	11	RoW	Pembrolizumab, KEYTRUDA, CVA21, CAVATAK, Coxsackie virus 21	Olivia Newton-John Cancer Research Institute, Merck Sharp & Dohme LLC, Viralytics	Non-Small Cell Lung Cancer	07/21	10/21